Nearly all the current inhibitors of Stat3 are low in potency (micro-molar) [3,7], except the recently reported PROTAC-Stat3 inhibitors, including SD-36, which degrades cellular Stat3, with nanomolar potency and inhibits tumor growth [8,9]. Here, STAT3 is linked to neoplasm.